JIMMY STEPHANO DUMORNAY
Pharmacy at Andrew Aviles Cir, Tampa, FL
License number
Florida PS39154
Category
Pharmacy
Type
Pharmacist
Address
Address
1117 Andrew Aviles Cir, Tampa, FL 33619
Phone
(781) 775-7182
(813) 476-7724
(813) 476-7724
Personal information
See more information about JIMMY STEPHANO DUMORNAY at radaris.comName
Address
Phone
9405 Crescent Loop Cir, Tampa, FL 33619
1117 Andrew Aviles Cir, Tampa, FL 33619
Professional information
9-Substituted Minocycline Compounds
US Patent:
2012028, Nov 8, 2012
Filed:
Jul 12, 2012
Appl. No.:
13/547870
Inventors:
Mark L. Nelson - Norfolk MA, US
Roger Frechette - Reading MA, US
Peter Viski - Chestnut Hill MA, US
Mohamed Y. Ismail - Bedford MA, US
Todd Bowser - Charlton MA, US
Jimmy Dumornay - Tampa FL, US
Glen Rennie - South Weymouth MA, US
Gui Liu - Lexington MA, US
Darrell J. Koza - Willimantic CT, US
Paul Sheahan - Hopkinton MA, US
Karen Stapleton - Weymouth MA, US
Paul Hawkins - Santa Fe NM, US
Atul K. Verma - Mansfield MA, US
Laura Honeyman - London, CA
Tadeusz Warchol - Northborough MA, US
David Messersmith - Somerville MA, US
Roger Frechette - Reading MA, US
Peter Viski - Chestnut Hill MA, US
Mohamed Y. Ismail - Bedford MA, US
Todd Bowser - Charlton MA, US
Jimmy Dumornay - Tampa FL, US
Glen Rennie - South Weymouth MA, US
Gui Liu - Lexington MA, US
Darrell J. Koza - Willimantic CT, US
Paul Sheahan - Hopkinton MA, US
Karen Stapleton - Weymouth MA, US
Paul Hawkins - Santa Fe NM, US
Atul K. Verma - Mansfield MA, US
Laura Honeyman - London, CA
Tadeusz Warchol - Northborough MA, US
David Messersmith - Somerville MA, US
Assignee:
Trustees of Tufts College - Medford MA
Paratek Pharmaceuticals, Inc. - Boston MA
Paratek Pharmaceuticals, Inc. - Boston MA
International Classification:
A61K 31/65, C07C 275/40, C07C 271/30, C07D 307/81, C07D 333/24, C07D 317/60, C07F 9/40, A61K 31/662, C07C 311/21, C07C 255/60, C07F 7/10, A61K 31/695, C07D 295/155, C07C 275/54, C07C 335/20, C07C 311/05, C07D 213/56, C07C 279/18, C07H 15/203, A61K 31/7034, A61P 31/04, A61P 35/00, C07D 213/64, C07C 237/26
US Classification:
514 25, 552205, 514152, 549469, 549 77, 549441, 514119, 514 63, 544380, 546285, 536 179
Abstract:
The present invention pertains, at least in part, to novel 9-substituted minocycline compounds. These minocycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for minocycline and tetracycline compounds in general, such as blocking tetracycline efflux and modulation of gene expression.
9-Substituted Minocycline Compounds
US Patent:
2009032, Dec 31, 2009
Filed:
Jan 9, 2009
Appl. No.:
12/351405
Inventors:
Mark L. Nelson - Norfolk MA, US
Roger Frechette - Reading MA, US
Peter Viski - Chestnut Hill MA, US
Mohamed Y. Ismail - Bedford MA, US
Todd Bowser - Charlton MA, US
Jimmy Dumornay - Tampa FL, US
Glen Rennie - South Weymouth MA, US
Gui Liu - Lexington MA, US
Darrell J. Koza - Wakefield RI, US
Paul Sheahan - Hopkinton MA, US
Karen Stapleton - Weymouth MA, US
Paul Hawkins - Santa Fe NM, US
Beena Bhatia - Mansfield MA, US
Atul K. Verma - Mansfield MA, US
Laura Honeyman - London, CA
Tadeusz Warchol - Northborough MA, US
David Messersmith - Somerville MA, US
Roger Frechette - Reading MA, US
Peter Viski - Chestnut Hill MA, US
Mohamed Y. Ismail - Bedford MA, US
Todd Bowser - Charlton MA, US
Jimmy Dumornay - Tampa FL, US
Glen Rennie - South Weymouth MA, US
Gui Liu - Lexington MA, US
Darrell J. Koza - Wakefield RI, US
Paul Sheahan - Hopkinton MA, US
Karen Stapleton - Weymouth MA, US
Paul Hawkins - Santa Fe NM, US
Beena Bhatia - Mansfield MA, US
Atul K. Verma - Mansfield MA, US
Laura Honeyman - London, CA
Tadeusz Warchol - Northborough MA, US
David Messersmith - Somerville MA, US
International Classification:
A61K 31/65, C07C 237/26
US Classification:
514152, 552205
Abstract:
The present invention pertains, at least in part, to novel 9-substituted minocycline compounds. These minocycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for minocycline and tetracycline compounds in general, such as blocking tetracycline efflux and modulation of gene expression.